Peter W. Rodino, III net worth and biography

Peter Rodino, III Biography and Net Worth

COO, Executive Director for Governmental Relations, General Counsel, Secretary of AIM ImmunoTech

PETER W. RODINO, III, J.D., was named Executive Director for Governmental Relations and General Counsel in October 2016 and Secretary in November 2016. Mr. Rodino was appointed a Director of the Company in July 2013 and served in that capacity until his resignation to permit him to serve the company in this new capacity. While on the Board, he served as Lead Director, Chairman and Financial Expert of the Audit Committee; as a member of the Compensation Committee; and as a member of the Governance and Nomination Committee. Mr. Rodino has broad legal, financial and executive experience. In addition to being President of Rodino Consulting LLC and managing partner at several law firms during his many years as a practicing attorney, he served as Chairman and CEO of Crossroads Health Plan, the first major Health Maintenance Organization in New Jersey. He also has experience as an investment executive in the securities industry and acted as trustee in numerous Chapter 11 complex corporate reorganizations. Mr. Rodino holds a Juris Doctor degree from Seton Hall University and a Bachelor of Science in Business Administration from Georgetown University.

What is Peter W. Rodino, III's net worth?: The estimated net worth of Peter W. Rodino, III is at least $5.90 thousand as of April 4th, 2025. Mr. Rodino, III owns 4,017 shares of AIM ImmunoTech stock worth more than $5,905 as of December 5th. This net worth evaluation does not reflect any other investments that Mr. Rodino, III may own. Learn More about Peter W. Rodino, III's net worth.
How do I contact Peter W. Rodino, III?: The corporate mailing address for Mr. Rodino, III and other AIM ImmunoTech executives is 2117 SW HIGHWAY 484, OCALA FL, 34473. AIM ImmunoTech can also be reached via phone at (352) 448-7797 and via email at [email protected]. Learn More on Peter W. Rodino, III's contact information.
Has Peter W. Rodino, III been buying or selling shares of AIM ImmunoTech?: Peter W. Rodino, III has not been actively trading shares of AIM ImmunoTech during the last ninety days. Most recently, on Friday, April 4th, Peter W. Rodino III bought 5 shares of AIM ImmunoTech stock. The stock was acquired at an average cost of $9.00 per share, with a total value of $45.00. Following the completion of the transaction, the chief operating officer now directly owns 4,017 shares of the company's stock, valued at $36,153. Learn More on Peter W. Rodino, III's trading history.
Who are AIM ImmunoTech's active insiders?: AIM ImmunoTech's insider roster includes Nancy Bryan (Director), Thomas Equels (CEO), and Peter Rodino, III (COO, Executive Director for Governmental Relations, General Counsel, Secretary). Learn More on AIM ImmunoTech's active insiders.
Are insiders buying or selling shares of AIM ImmunoTech?: In the last twelve months, AIM ImmunoTech insiders bought shares 4 times. They purchased a total of 1,475 shares worth more than $17,268.00. The most recent insider tranaction occured on April, 4th when COO Peter W Rodino III bought 5 shares worth more than $45.00. Insiders at AIM ImmunoTech own 0.0% of the company. Learn More about insider trades at AIM ImmunoTech.
Information on this page was last updated on 4/4/2025.

Peter W. Rodino, III Insider Trading History at AIM ImmunoTech

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
4/4/2025	Buy	5	$9.00	$45.00	4,017
5/6/2024	Buy	308	$41.00	$12,628.00	2,125
3/15/2024	Buy	378	$33.00	$12,474.00	1,817

Peter W. Rodino, III Buying and Selling Activity at AIM ImmunoTech

AIM ImmunoTech Company Overview

AIM ImmunoTech Inc., an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders in the United States. The company's lead product candidate is Ampligen, a drug of macromolecular ribonucleic acid molecules for the treatment of chronic fatigue syndrome (CFS). It is also developing Ampligen for the treatment of pancreatic, renal cell carcinoma, malignant melanoma, non-small cell lung, ovarian, breast, colorectal, and prostate cancers, as well as for myalgic encephalomyelitis, Hepatitis B, HIV, COVID-19, and post-COVID conditions. In addition, the company provides Alferon N Injection, an injectable formulation of natural alpha interferon to treat human papilloma viruses, and genital warts, a sexually transmitted disease. AIM ImmunoTech Inc. has agreements with Amarex Clinical Research LLC; University of Cagliari Dipartimento di Scienze della Vita e dell'Ambiente; Jubilant HollisterStier; Sterling Pharma Solutions; Erasmus University Medical Center Rotterdam; Azenova, LLC; and Alcami Corporation. The company was formerly known as Hemispherx Biopharma, Inc. and changed its name to AIM ImmunoTech Inc. in August 2019. AIM ImmunoTech Inc. was incorporated in 1966 and is headquartered in Ocala, Florida.

Today's Range

Now: $1.47

$1.41

$1.51

50 Day Range

MA: $2.07

$1.30

$2.76

2 Week Range

Now: $1.47

$1.26

$36.00

Volume

45,964 shs

Average Volume

59,631 shs

Market Capitalization

$4.19 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.19